Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568638 | 0.87 | PDK2 (0.34) | CDK4CCND1GSK3BALDH1A1KDM4E | |
| SCHEMBL30125362 | 0.73 | PDK2 (0.40) | ALDH1A1KDM4ELMNAMDM2SMN1; SMN2 | |
| SCHEMBL165110 | 0.73 | PDK2 (0.40) | ALDH1A1KDM4ELMNAMDM2SMN1; SMN2 | |
| SCHEMBL4568630 | 0.73 | PARP1 (0.31) | PDK2 | |
| SCHEMBL18351750 | 0.72 | PDK2 (0.40) | ALDH1A1KDM4ELMNAMDM2SMN1; SMN2 | |
| SCHEMBL30104202 | 0.71 | PDK2 (0.41) | ALDH1A1KDM4ELMNASMN1; SMN2PDK2 | |
| SCHEMBL2200232 | 0.71 | PDK2 (0.41) | ALDH1A1KDM4ELMNASMN1; SMN2PDK2 | |
| SCHEMBL12635549 | 0.69 | ESR1 (0.32) | — | |
| SCHEMBL4568684 | 0.68 | MLNR (0.30) | — | |
| SCHEMBL4568713 | 0.68 | ALOX5AP (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | CDK4 883/4885CCND1 288/4885GSK3B 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.